Class Action Reminder for New Era Energy and Gossamer Bio
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy GOSS?
Source: Globenewswire
- New Era Energy Lawsuit: A class action lawsuit against New Era Energy (NUAI) alleges that the company failed to disclose material facts regarding its Texas Critical Data Centers project from November 6, 2024, to December 29, 2025, resulting in significant investor losses, with a deadline of June 1, 2026, to apply as lead plaintiff.
- Gossamer Bio Lawsuit: A class action lawsuit against Gossamer Bio (GOSS) claims that the company made misleading statements regarding its Phase 3 PROSERA study between June 16, 2025, and February 20, 2026, with the same June 1, 2026, deadline for investors to seek lead plaintiff status.
- Law Firm Credentials: Holzer & Holzer, LLC, recognized as an ISS top-rated securities litigation firm from 2021 to 2025, is dedicated to vigorously representing shareholders and investors, having recovered hundreds of millions of dollars for victims of corporate misconduct since its inception in 2000.
- Investor Rights Advocacy: The firm encourages investors who purchased shares during the specified periods and suffered losses to contact their attorneys to understand their legal rights, ensuring they receive the necessary protection and support in the litigation process.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GOSS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GOSS
Wall Street analysts forecast GOSS stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.370
Low
10.00
Averages
12.33
High
15.00
Current: 0.370
Low
10.00
Averages
12.33
High
15.00
About GOSS
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Class Action Reminder for New Era Energy and Gossamer Bio
- New Era Energy Lawsuit: A class action lawsuit against New Era Energy (NUAI) alleges that the company failed to disclose material facts regarding its Texas Critical Data Centers project from November 6, 2024, to December 29, 2025, resulting in significant investor losses, with a deadline of June 1, 2026, to apply as lead plaintiff.
- Gossamer Bio Lawsuit: A class action lawsuit against Gossamer Bio (GOSS) claims that the company made misleading statements regarding its Phase 3 PROSERA study between June 16, 2025, and February 20, 2026, with the same June 1, 2026, deadline for investors to seek lead plaintiff status.
- Law Firm Credentials: Holzer & Holzer, LLC, recognized as an ISS top-rated securities litigation firm from 2021 to 2025, is dedicated to vigorously representing shareholders and investors, having recovered hundreds of millions of dollars for victims of corporate misconduct since its inception in 2000.
- Investor Rights Advocacy: The firm encourages investors who purchased shares during the specified periods and suffered losses to contact their attorneys to understand their legal rights, ensuring they receive the necessary protection and support in the litigation process.
See More
Gossamer Bio Accused of Misleading Investors in Class Action
- Class Action Filed: Robbins LLP reminds shareholders that a class action has been initiated on behalf of investors who purchased Gossamer Bio (NASDAQ: GOSS) securities between June 16, 2025, and February 20, 2026, alleging the company misled investors regarding its PROSERA study, causing shareholders to buy securities at artificially inflated prices.
- Study Results Fail: On February 23, 2026, Gossamer announced that its Phase 3 PROSERA study failed to meet its primary endpoint, achieving only a +13.3 meter placebo-adjusted gain in six-minute walk distance (6MWD), which did not meet the required 0.025 alpha threshold, leading to a stock price drop of over 80% in a single day.
- Investor Confidence Eroded: The concealment of issues related to placebo response control in the study design severely undermined investor confidence, with the stock price plummeting from $2.13 per share on February 20, 2026, to $0.42 per share on February 23, reflecting a pessimistic outlook on the company's future prospects.
- Shareholder Action Guidance: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by June 1, 2026, with Robbins LLP offering contingency fee representation, ensuring shareholders can potentially recover losses without upfront costs.
See More
Class Action Lawsuit Filed Against Gossamer Bio, Inc.
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Gossamer Bio, Inc., alleging violations of federal securities laws on behalf of all investors who purchased or acquired Gossamer securities between June 16, 2025, and February 20, 2026.
- False Statements Allegation: The complaint claims that Gossamer's executives concealed significant adverse facts regarding the Phase 3 PROSERA study while promoting positive results, particularly their failure to adequately control for placebo response at Latin American testing sites, which led to artificially inflated stock prices.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by June 1, 2026, to share in any potential recovery, with the assurance that participation does not require serving as lead plaintiff.
- Law Firm's Advantage: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions, having recovered hundreds of millions for investors, emphasizing their commitment to restoring investor capital and ensuring corporate accountability.
See More
Gossamer Bio Under Investigation for Possible Securities Law Violations
- Stock Price Plunge: On February 23, 2026, Gossamer Bio disclosed that its Phase 3 PROSERA study results failed to meet the primary endpoint, causing its stock price to plummet by 80.3% to close at $0.42 per share, severely impacting investor interests.
- Study Failure Impact: The study indicated that patients at Latin American sites performed well on placebo, reflecting a heavily-treated, lower-risk patient population, which exacerbated market concerns regarding the company's future prospects.
- Legal Investigation Initiated: The Law Offices of Howard G. Smith announced an investigation into Gossamer Bio to assess potential violations of federal securities laws, which could lead to legal actions for investors seeking to recover losses.
- Investor Rights Protection: The law firm is urging all investors who suffered losses in Gossamer Bio to reach out to discuss potential claims, demonstrating a commitment to protecting investor rights and interests.
See More
Gossamer Bio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Gossamer Bio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between June 16, 2025, and February 20, 2026, with a deadline to contact the firm by June 1, 2026.
- False Statement Allegations: The complaint alleges that Gossamer concealed adverse facts regarding the design of its Phase 3 PROSERA study, particularly concerning controls for placebo response at certain testing sites, rendering its public statements false and materially misleading throughout the class period.
- Investor Losses: As the market learned the truth about Gossamer, investors suffered damages, indicating significant deficiencies in the company's disclosure practices that could impact future stock performance and investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to take action before class certification to ensure their rights are protected and avoid being absent class members.
See More
Faruqi & Faruqi Investigates Gossamer Investor Losses
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating Gossamer Bio, Inc. for potential investor losses incurred between June 16, 2025, and February 20, 2026, indicating the company may face legal liabilities that could impact its market reputation.
- Investor Rights Reminder: The firm reminds investors that June 1, 2026, is the deadline to seek lead plaintiff status in a federal securities class action, emphasizing the need for timely action to protect their rights, which could affect future claims outcomes.
- Direct Contact Channels: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 or 212-983-9330, demonstrating a commitment to supporting investor rights and concerns.
- Potential Claim Opportunities: This investigation may offer investors a chance to file claims, and if Gossamer is found to have engaged in wrongdoing, affected investors could receive compensation, further influencing the company's stock price and investor confidence.
See More
Class Action Reminder for New Era Energy and Gossamer Bio
- New Era Energy Lawsuit: A class action lawsuit against New Era Energy (NUAI) alleges that the company failed to disclose material facts regarding its Texas Critical Data Centers project from November 6, 2024, to December 29, 2025, resulting in significant investor losses, with a deadline of June 1, 2026, to apply as lead plaintiff.
- Gossamer Bio Lawsuit: A class action lawsuit against Gossamer Bio (GOSS) claims that the company made misleading statements regarding its Phase 3 PROSERA study between June 16, 2025, and February 20, 2026, with the same June 1, 2026, deadline for investors to seek lead plaintiff status.
- Law Firm Credentials: Holzer & Holzer, LLC, recognized as an ISS top-rated securities litigation firm from 2021 to 2025, is dedicated to vigorously representing shareholders and investors, having recovered hundreds of millions of dollars for victims of corporate misconduct since its inception in 2000.
- Investor Rights Advocacy: The firm encourages investors who purchased shares during the specified periods and suffered losses to contact their attorneys to understand their legal rights, ensuring they receive the necessary protection and support in the litigation process.
See More
Gossamer Bio Accused of Misleading Investors in Class Action
- Class Action Filed: Robbins LLP reminds shareholders that a class action has been initiated on behalf of investors who purchased Gossamer Bio (NASDAQ: GOSS) securities between June 16, 2025, and February 20, 2026, alleging the company misled investors regarding its PROSERA study, causing shareholders to buy securities at artificially inflated prices.
- Study Results Fail: On February 23, 2026, Gossamer announced that its Phase 3 PROSERA study failed to meet its primary endpoint, achieving only a +13.3 meter placebo-adjusted gain in six-minute walk distance (6MWD), which did not meet the required 0.025 alpha threshold, leading to a stock price drop of over 80% in a single day.
- Investor Confidence Eroded: The concealment of issues related to placebo response control in the study design severely undermined investor confidence, with the stock price plummeting from $2.13 per share on February 20, 2026, to $0.42 per share on February 23, reflecting a pessimistic outlook on the company's future prospects.
- Shareholder Action Guidance: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by June 1, 2026, with Robbins LLP offering contingency fee representation, ensuring shareholders can potentially recover losses without upfront costs.
See More
Class Action Lawsuit Filed Against Gossamer Bio, Inc.
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Gossamer Bio, Inc., alleging violations of federal securities laws on behalf of all investors who purchased or acquired Gossamer securities between June 16, 2025, and February 20, 2026.
- False Statements Allegation: The complaint claims that Gossamer's executives concealed significant adverse facts regarding the Phase 3 PROSERA study while promoting positive results, particularly their failure to adequately control for placebo response at Latin American testing sites, which led to artificially inflated stock prices.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by June 1, 2026, to share in any potential recovery, with the assurance that participation does not require serving as lead plaintiff.
- Law Firm's Advantage: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions, having recovered hundreds of millions for investors, emphasizing their commitment to restoring investor capital and ensuring corporate accountability.
See More
Gossamer Bio Under Investigation for Possible Securities Law Violations
- Stock Price Plunge: On February 23, 2026, Gossamer Bio disclosed that its Phase 3 PROSERA study results failed to meet the primary endpoint, causing its stock price to plummet by 80.3% to close at $0.42 per share, severely impacting investor interests.
- Study Failure Impact: The study indicated that patients at Latin American sites performed well on placebo, reflecting a heavily-treated, lower-risk patient population, which exacerbated market concerns regarding the company's future prospects.
- Legal Investigation Initiated: The Law Offices of Howard G. Smith announced an investigation into Gossamer Bio to assess potential violations of federal securities laws, which could lead to legal actions for investors seeking to recover losses.
- Investor Rights Protection: The law firm is urging all investors who suffered losses in Gossamer Bio to reach out to discuss potential claims, demonstrating a commitment to protecting investor rights and interests.
See More
Gossamer Bio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Gossamer Bio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between June 16, 2025, and February 20, 2026, with a deadline to contact the firm by June 1, 2026.
- False Statement Allegations: The complaint alleges that Gossamer concealed adverse facts regarding the design of its Phase 3 PROSERA study, particularly concerning controls for placebo response at certain testing sites, rendering its public statements false and materially misleading throughout the class period.
- Investor Losses: As the market learned the truth about Gossamer, investors suffered damages, indicating significant deficiencies in the company's disclosure practices that could impact future stock performance and investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to take action before class certification to ensure their rights are protected and avoid being absent class members.
See More
Faruqi & Faruqi Investigates Gossamer Investor Losses
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating Gossamer Bio, Inc. for potential investor losses incurred between June 16, 2025, and February 20, 2026, indicating the company may face legal liabilities that could impact its market reputation.
- Investor Rights Reminder: The firm reminds investors that June 1, 2026, is the deadline to seek lead plaintiff status in a federal securities class action, emphasizing the need for timely action to protect their rights, which could affect future claims outcomes.
- Direct Contact Channels: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 or 212-983-9330, demonstrating a commitment to supporting investor rights and concerns.
- Potential Claim Opportunities: This investigation may offer investors a chance to file claims, and if Gossamer is found to have engaged in wrongdoing, affected investors could receive compensation, further influencing the company's stock price and investor confidence.
See More
